NIKKEI 225
38,592.76 -242.34 (-0.62%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.23 -0.15 (-0.19%) GOLD FUTURES
2,323.20 -1.00 (-0.04%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
49,940.34 -646.57 (-1.28%)
BEAM Dec 2024 30.000 put
| Previous close | 9.93 |
| Open | 8.80 |
| Bid | 9.70 |
| Ask | 10.60 |
| Strike | 30.00 |
| Expiry date | 2024-12-20 |
| Day's range | 8.80 - 9.93 |
| Contract range | N/A |
| Volume | |
| Open interest | 244 |
GlobeNewswireBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM-301 On Track for Submission of U.S. Investigational New Drug (IND) Application in First Half of 2024 Ended First Quarter 2024 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities;
ZacksUltragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.02% and 4.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksBeam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
